Phase 3 Trial for Inovio’s VGX-3100 in Cervical Dysplasia Gets FDA Go-Ahead

Source: The Life Sciences Report   06/14/2017 Now that the FDA has lifted its clinical hold on Phase 3 study of Inovio Pharmaceutical’s immunotherapy for cervical dysplasia, three analysts are making note . . . → Read More: Phase 3 Trial for Inovio’s VGX-3100 in Cervical Dysplasia Gets FDA Go-Ahead Similar Articles: Trial Results Set Up DURECT Corp. for ‘Exciting Year’ RepliCel’s Phase 1 Trial for Hair Loss Completed Successfully Inovio’s Zika Vaccine Generates Robust Immune Responses